Answers are grounded in this paper and cite their sources.
With the expanding use of sodium-glucose cotransporter 2 inhibitors, pharmacovigilance data can help characterize rare but serious adverse drug reactions such as diabetic ketoacidosis. To describe the clinical spectrum and age-related differences in sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis and identify distinct clinical presentation patterns using the French Pharmacovigilance Database. We conducted a retrospective nationwide case-series study including all expert-adjudicated reports of sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis recorded in the French Pharmacovigilance Database up to December 31, 2025. Clinical characteristics were compared between patients aged < 65 and ≥ 65 years. Unsupervised clustering was used to identify clinical presentation patterns. Among 299 reports screened, 242 expert-adjudicated cases of ketoacidosis were included (median age 67 years [interquartile range 57–76]; 43% women), of which 88 (36%) fulfilled all three 2024 ADA/EASD diagnostic domains. Euglycemic DKA occurred in 64/165 patients with available blood glucose data (39%), moderate-to-severe metabolic acidosis in 107/177 patients with available pH data (60%), and 100/240 patients with available ICU data (42%) were admitted to an ICU. Three clinical presentation patterns were identified: (1) a fasting-related phenotype characterized by gastrointestinal symptoms and fasting; (2) a perioperative phenotype associated with recent surgery; and (3) an infection-related phenotype characterized by infection, neurological symptoms, and falls, predominantly affecting older patients. Neither moderate-to-severe acidosis nor ICU admission differed significantly between age groups. Sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis shows heterogeneous presentations in routine practice. Older adults more often presented with atypical manifestations, whereas younger patients more often exhibited gastrointestinal symptoms. In older adults receiving sodium-glucose cotransporter 2 inhibitors, ketoacidosis should be considered when infection, neurological symptoms, or falls occur, even in the absence of gastrointestinal symptoms.
No takes yet. Share an insight, caveat, or question.
Letissier et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: